Skip to main content

Table 3 Treatments in the study analysis population as a function of treating physician

From: Management of osteoporosis and associated quality of life in post menopausal women

  GPs
N = 810
Rheumatologists
N = 317
Gynaecologists
N = 179
p Total
N = 1306
ON GOING TREATMENT 526 (64.9%) 150 (47.3%) 70 (39.1%) ≤ 0.001 746 (57.1%)
   Bisphosphonates 412 (78.3%) 98 (65.3%) 33 (47.1%) ≤ 0.001 543 (72.8%)
Daily 14 (3.5%) 2 (2.1%) 1 (3.2%) NS 17 (3.2%)
Weekly 227 (56.9%) 60 (63.8%) 18 (58.1%)   305 (58.2%)
Monthly 158 (39.6%) 32 (34.0%) 12 (38.7%)   202 (38.6%)
   SERM 47 (8.9%) 14 (9.3%) 15 (21.4%) 0.009 76 (10.2%)
   Strontium ranelate 68 (12.9%) 34 (22.7%) 17 (24.3%) 0.003 119 (16.0%)
   Other 10 (1.9%) 4 (2.7%) 12 (17.1%) ≤ 0.001 26 (3.5%)
SUPPLEMENTATION 671 (82.8%) 269 (84.9%) 146 (81.6%) NS 1086 (83.2%)
Supplementation Type N = 655 N = 268 N = 141   N = 1064
   Calcium 33 (5.0%) 7 (2.6%) 3 (2.1%) 0.073 43 (4.0%)
   Vitamin D 27 (4.1%) 20 (7.5%) 9 (6.4%)   56 (5.3%)
   Calcium + Vitamin D 595 (90.8%) 241 (89.9%) 129 (91.5%)   965 (90.7%)
  1. For the individual osteoporosis treatments, only treatments ongoing at the time of the consultation are considered. Percentages for individual treatments are calculated with respect to the total number of patients with an ongoing treatment. Percentages for bisphosphonate treatment regimens are calculated with respect to the total number of patients taking a bisphosphonate. Percentages for supplementation type are calculated with respect to the total number of patients taking supplementation. SERM: selective oestrogen receptor modulators. NS: not significant. Between group differences were determined with the Kruskal-Wallis test.